Showing results (221-230 of 491) with videos related to
Sort By:
Pageof 50
Journal of Vascular Surgery|January 1, 1987
Neointimal hyperplasia occurring after carotid endarterectomy in a canine model: effect of endothelial cell seeding vs. perioperative aspirinH L Bush, J A Jakubowski, J M Sentissi, et al.Platelets|September 1, 2007
Clopidogrel poor responders: an objective definition based on Bayesian classificationGovinda J Weerakkody, John T Brandt, Christopher D Payne, et al.Journal of Cardiovascular Pharmacology and Therapeutics|September 19, 2007
Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysisGovinda J Weerakkody, Joseph A Jakubowski, John T Brandt, et al.Leukemia|November 1, 1995
A pilot study of the biologic and therapeutic effects of granulocyte colony-stimulating factor (filgrastim) in patients with acute myelogenous leukemiaA Jakubowski, M Gordon, A Tafuri, et al.Journal of Thrombosis and Haemostasis : JTH|January 17, 2014
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratificationM J Price, B A Baker, J A Jakubowski, et al.Current Hematologic Malignancy Reports|February 9, 2024
Transplantation and Cellular Therapy for Older Adults-The MSK ApproachRichard J Lin, Parastoo B Dahi, Beatriz Korc-Grodzicki, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1990
A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expressionD A Scheinberg, D J Straus, S D Yeh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1991
A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclideD A Scheinberg, D Lovett, C R Divgi, et al.Leukemia|February 1, 1995
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195J G Jurcic, P C Caron, W H Miller, et al.Growth Factors (Chur, Switzerland)|January 1, 1997
Low level expression of basic FGF upregulates Bcl-2 and delays apoptosis, but high intracellular levels are required to induce transformation in NIH 3T3 cellsR Wieder, H Wang, S Shirke, et al.Pageof 50